Mass. molecular Dx firm boosts IPO goal to $92M

09/17/2013 | Clinica (subscription required)

Foundation Medicine, which earlier announced plans to raise a maximum of $86 million in an initial public offering, has boosted its IPO target to as much as $92 million. The Cambridge, Mass.-based molecular diagnostics firm plans to use part of the proceeds to increase its sales force and to support ongoing and new clinical studies.

View Full Article in:

Clinica (subscription required)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health